News

Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of 10 Stocks Are Dominating Like Wall Street Titans. In this article, we are going to take a ...
Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT
Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, ...
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
BioPharma Dive4d
Insmed surges on lung drug data; Recursion cuts staff
Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations.
Protein-binding affinity model expands role of AI in drug discovery
Understanding how molecules interact is central to biology: from decoding how living organisms function to uncovering disease mechanisms and developing life-saving drugs. In recent years, models like ...
BioSpace5d
Recursion Downsizes by 20% To Boost Cash Position
Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to ...
Optimizing AI apps in a million-token world
The context size problem in large language models is nearly solved. Here's why that brings up new questions about how we ...